Does Lurbinectedin Cause Birth Defects or Fetal Harm?
Lurbinectedin ( Zepzelca), approved for small cell lung cancer, is classified as pregnancy category D by the FDA, meaning human studies show fetal risk but potential benefits may justify use in life-threatening conditions.[1] Animal data confirm it harms developing fetuses: in rats and rabbits, it caused embryo-fetal lethality, reduced fetal weight, and abnormalities like skeletal malformations, reduced ossification, and visceral changes at doses below human equivalents.[2]
What Do Clinical Warnings Say?
The prescribing label states lurbinectedin can cause fetal harm based on its mechanism (DNA damage via transcription inhibition) and animal reproduction studies. It advises women of childbearing potential to use effective contraception during treatment and for 6 months after the last dose. Men with female partners of reproductive potential should use contraception during treatment and for 4 months post-dose. No human pregnancy data exist due to exclusion of pregnant patients from trials.[2][3]
What Happens in Exposed Pregnancies?
No controlled human studies report outcomes, but the label recommends pregnancy testing before starting and immediate action (discontinuation, verification) if pregnancy occurs. If exposed, fetal ultrasound and amniocentesis for chromosomal abnormalities are suggested, though evidence on reversibility is absent. Postmarketing reports are limited, but alkylating-like agents (similar class) increase miscarriage and congenital malformation risks.[2]
How Does It Compare to Other Chemotherapy Drugs?
Like platinum-based chemotherapies (e.g., cisplatin), lurbinectedin is embryotoxic due to rapid cell division disruption in fetuses. Unlike some targeted therapies, it lacks human safety data in pregnancy, making it riskier than non-genotoxic options. Oncologists weigh maternal survival against fetal loss, often delaying treatment or using alternatives if possible.[4]
Patient and Fertility Advice
Advise avoiding pregnancy; female patients must verify non-pregnant status via test. It may impair male fertility (animal data show testicular toxicity), though human impact is unclear. Breastfeeding is contraindicated as it enters milk and harms infants.[2]
Sources
[1]: FDA Label, Zepzelca (lurbinectedin), 2020. link
[2]: Zepzelca Prescribing Information, Jazz Pharmaceuticals. link
[3]: Drugs.com, Lurbinectedin Pregnancy. link
[4]: American Society of Clinical Oncology, Chemotherapy in Pregnancy Guidelines. link